All In Biotech

Drug Trial Radar · NCT03458559

Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy

Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study

Last checked: Nov 20, 2026Latest source record: Nov 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

402

Planned (sponsor's estimate)

Start

May 16, 2018

Primary completion

May 16, 2022

Study completion May 16, 2024

Sponsor

Lead sponsor
Amsterdam UMC, location VUmcAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone. Beta-emitting radiopharmaceuticals have proven efficacy for palliating malignant bone pain. Nowadays, rhenium-188-HEDP is used in clinical practice for pain relief and palliative care. Several studies suggest that also rhenium-188-HEDP has the potential to improve overall survival. The purpose of this study is to investigate if treatment with rhenium-188-HEDP results in improvement of overall survival compared to treatment with radium-223-chloride.

Conditions

  • Prostate Cancer Metastatic to Bone

Interventions

  • Radium-223 chlorideDrug

    Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations

  • Rhenium-188-HEDPDrug

    Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: Time from randomization until death due to any cause, an average of 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VU University Medical Center

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.